Update on Wegener granulomatosis
Carol A. Langford, MD, MHS
Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation
Address: Carol Langford, MD, MHS, Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
No therapeutic agents are specifically approved for the treatment of Wegener granulomatosis. All references to a commercial product constitute an unlabeled use.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.
ABSTRACTWegener granulomatosis classically involves clinical disease of the upper airways, lungs, and kidneys. Ninety percent of patients present with symptoms involving the upper or lower airways, or both, and it should be suspected in any patient with pulmonary hemorrhage, glomerulonephritis, mononeuritis multiplex, unexplained multisystem disease, or progressive unresponsive sinus disease. Current treatments induce remission and allow long-term survival.